Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DDHD2, whose mutation causes spastic paraplegia type 54, is cargo receptor for lipophagy

ABSTRACT: DDHD2 mutation was a common cause of SPG54 disease. While its mechanism of action was unclear, we aimed to comprehensively characterize the DDHD2 interactome networks in cells. To achieve this, we used affinity purification coupled with mass spectrometry (AP-MS) to define the interactome for DDHD2. We transiently transfected FLAG-DDHD2 expression plasmids into 293T cells, and then performed whole cell lysis for FLAG immunoprecipitation followed by mass spectrometry analysis (IP-MS). As a result, we identified components of the autophagy complex that were enriched in the interactome of DDHD2

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

SUBMITTER: fei jia

LAB HEAD: Chengji Wang

PROVIDER: PXD044430 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Exploris04008-SKY-WCJ-JF-20230706-DDHD2.pdResult	Other
	Exploris04008-SKY-WCJ-JF-20230706-DDHD2.raw	Raw

Items per page:

1 - 2 of 2

Publications

DDHD2, whose mutations cause spastic paraplegia type 54, enhances lipophagy via engaging ATG8 family proteins.

Jia Fei F Wang Xiaoman X Fu Yuhua Y Zhao Shi-Min SM Lu Boxun B Wang Chenji C

Cell death and differentiation 20240208 3

Hereditary spastic paraplegia (HSP) is a group of inherited neurodegenerative disorders characterized by progressive lower limb spasticity and weakness. One subtype of HSP, known as SPG54, is caused by biallelic mutations in the DDHD2 gene. The primary pathological feature observed in patients with SPG54 is the massive accumulation of lipid droplets (LDs) in the brain. However, the precise mechanisms and roles of DDHD2 in regulating lipid homeostasis are not yet fully understood. Through Affinit ...[more]

PMID: 38332048

Similar Datasets

Define the interactome of IBTK by Affinity purification coupled with mass spectrometry (AP-MS) and proximity-dependent biotinylation identification (BioID) methods

Project description:Affinity purification coupled with mass spectrometry (AP-MS) and proximity-dependent biotinylation identification (BioID) methods are powerful tools to define the interactome for a specific protein bait. Whereas AP-MS results in the identification of proteins that are in a stable complex, BioID labels and identifies proteins that are in close proximity to the bait, resulting in overlapping yet distinct protein identifications. In order to comprehensively characterize the IBTK interactome networks in cells, we developed a tag workflow which allows for both AP-MS and BioID analysis with a single construct, pcDNA5/FRT vector containing FLAG-BirA-IBTK.

2024-05-10 | PXD038286 | Pride

Identify the interacting proteins of FBXL4 by AP-MS

Project description:Affinity purification coupled with mass spectrometry (AP-MS) is powerful tools to define the interactome for a specific protein bait. Whereas AP-MS results in the identification of proteins that are in a stable complex.Mass spectrometry was performed to identify the interacting proteins of FBXL4 from FBXL4 -containing protein complexes.

2024-05-12 | PXD040601 | Pride

The identification of ubiquitination sites of IBTK by shotgun proteomics

Project description:Previous study reported that eIF4A1 protein stability is subject to control by the ubiquitin-proteasome pathway, and deubiquitinase USP9X elevated eIF4A1 protein level by promoting eIF4A1 deubiquitination. However, the E3 ubiquitin ligases responsible for eIF4A1 proteolysis is not determined. Our research suggested that IBTK mediated non-degradative ubiquitination of eIF4A1, thus probable ubiquitination sites of eIF4A1 were identified by MS analysis.

2024-05-10 | PXD039031 | Pride

The identification of phosphorylation sites of IBTK by shotgun proteomics

Project description:Translation is a tightly regulated process, and the mTORC1-S6K signaling axis plays a critical role in this control. Binding of eIF4F to the cap is hindered by eIF4E binding proteins (4EBPs), which, when hypophosphorylated, sequester eIF4E and prevent its association with eIF4G. However, in response to positive stimuli such as growth factors, mitogens, and amino acids, mTORC1 phosphorylates 4EBPs and relieves this inhibition, allowing the formation of eIF4F and subsequent initiation of translation. We are interested to know whether IBTK-mediated eIF4A1 ubiquitination is regulated by mTORC1/S6K signaling. Indeed, quantitative phosphoproteomics studies revealed that several IBTK phosphorylation sites are markedly downregulated by treatment of mTOR inhibitor, Rapamycin or Torin 1. Thus, probable phosphorylation sites of IBTK were identified by MS analysis.

2024-05-10 | PXD038307 | Pride

in vitro kinase assays Identified of STAT1 phosphorylation sites-mediated LATS2

Project description:LATS1/2 are frequently down-regulated or mutated in endometrial cancer (EC), yet their exact role in endometrial tumor progression remains unclear. In this study, we unexpectedly discovered a new function of LATS1/2 in regulating MHC class I expression in EC. Knockout of LATS1/2 in EC cells led to significant down-regulation of multiple genes within the MHC/HLA Class I family, which weakened the killing effects of PBMCs on tumor cells. Importantly, we found that the regulation of MHC/HLA expression by LATS1/2 does not depend on the classical Hippo pathway but rather involves their direct interaction with STAT1. This interaction causes STAT1 to be phosphorylated at Ser727 or Ser532, promoting its accumulation and movement into the nucleus and enhancing the transcriptional activation of IRF1/NLRC5 on MHC-I. Additionally, we demonstrated that the kinase-dead mutant LATS1/2 weakens STAT1 phosphorylation at Ser727, supporting our findings. Our results show a positive correlation between the expression levels of LATS1/2, MHC-I, CD8, and p-STAT1 in tissue samples of EC, providing further evidence to support our discoveries. Overall, our findings reveal novel molecular mechanisms underlying tumor immunogenicity deficiency and suggest that LATS1/2 may serve as an immunotherapy biomarker for targeting EC.

2024-06-16 | PXD043500 | Pride

Amuc_2172 tandem affinity purification LCMSMS

Project description:Histone lysine lactylation (Klac) is a new posttranslational modification (PTM) that is installed by acetyltransferase to modulate specific immune responses1 and oncogenesis2,3. Akkermansia muciniphila (A. muciniphila) is a beneficial bacterium that blunts ulcerative colitis (UC) in a mouse model by secreting extracellular vesicles (SEVs)4. Although many histone sites are known to contain lysine lactylation, whether this modification is regulated to modulate specific biological functions by exogenous acetyltransferase or intestinal microbiota is not well understood. Here, we discovered that SEV from A. muciniphila, rather than A. muciniphila per se, has anti-Th17 (T helper 17) differentiation activity. We further screened the composition of SEV and found that Amuc_2172 is the key active component. As a GCN5-related acetyltransferase of A. muciniphila, Amuc_2172 is accessible to naïve T cells and functions as a lactylation transferase on Lys4 of histone H3. Accelerated histone H3 lactylation (H3Klac) on Lys4 competitively blocks trimethylation (H3Kme3) on Il17a loci in the process of Th17-cell differentiation. Additionally, intraperitoneal application of recombinant Amuc_2172 also inhibited Th17 and dextran sulfate sodium (DSS)-induced UC phenotypes in vivo; moreover, bioengineered Amuc_2172 showed improved colitis site delivery and higher Th17 inhibition potential compared to Amuc_2172 alone. Our study reveals not only a potential therapeutic strategy for treating colitis but also a model via which lysine lactylation is regulated by the intestinal microbiota, which may be broadly applicable to understand the crosstalk of bacteria and immunity.

2023-11-29 | PXD037142 | Pride

Effects of EVI1 and EVI1?324 mild expression in HeLa cells

Project description:We studied the variations of mRNA amounts after Flag-EVI1, Flag-EVI1?324, or Flag expression in HeLa cells. Despites EVI1 discovery in 1988, its recognized role as a dominant oncogene in myeloid leukemia and more recently in epithelial cancers, only a few target genes were known and it was not clear why EVI1 was involved in cancer progression. Here we obtained the genomic binding occupancy and expression data for EVI1 in human cells. We identified numerous EVI1 target cancer genes and genes controlling cell migration and adhesion. Moreover, we characterized a transcriptional cooperation between AP1 and EVI1 that regulated proliferation and adhesion through a feed-forward loop. This study provides human genome-wide mapping and expression analyses for EVI1 that will be useful for the research community. 12 samples were collected. Each condition was done in 4 replicates, collected 24 hours after transfection (for mild expression of EVI1 or EVI1?324). Transfections with Flag-expressing vector were used as controls.

2012-11-14 | E-GEOD-42251 | biostudies-arrayexpress

Effects of EVI1 mild expression in HeLa cells

Project description:We studied the variations of mRNA amounts after Flag-EVI1 or Flag expression in HeLa cells. Despites EVI1 discovery in 1988, its recognized role as a dominant oncogene in myeloid leukemia and more recently in epithelial cancers, only a few target genes were known and it was not clear why EVI1 was involved in cancer progression. Here we obtained the genomic binding occupancy and expression data for EVI1 in human cells. We identified numerous EVI1 target cancer genes and genes controlling cell migration and adhesion. Moreover, we characterized a transcriptional cooperation between AP1 and EVI1 that regulated proliferation and adhesion through a feed-forward loop. Furthermore, this study provides human genome-wide mapping and downstream analyses for EVI1 that will be useful for the research community. 8 samples were collected. Each condition was done in 4 replicates, collected 24 hours after transfection (for mild expression of EVI1). Transfections with Flag-expressing vector were used as controls.

2012-01-15 | E-GEOD-33724 | biostudies-arrayexpress

EVI1 and AP1 Interact to Transcriptionally Regulate a Feed-Forward Loop Important for Cancer Cell Proliferation and Adhesion

Project description:This SuperSeries is composed of the following subset Series: GSE25210: Genome-wide mapping of Flag-Evi1 in SKOV-3 ovarian carcinoma cells GSE25212: Effects of Evi1 knockdown and overexpression in SKOV-3 ovarian carcinoma cells GSE33724: Effects of EVI1 mild expression in HeLa cells Refer to individual Series

2012-01-15 | E-GEOD-25213 | biostudies-arrayexpress

Effects of Evi1 knockdown and overexpression in SKOV-3 ovarian carcinoma cells

Project description:We studied the variations of mRNA amounts after Evi1 knockdown or Flag-Evi1 overexpression in SKOV-3 cells. Despites Evi1 discovery in 1988, its recognized role as a dominant oncogene in myeloid leukemia and more recently in epithelial cancers, only a few target genes were known and it was not clear why Evi1 was involved in cancer progression. Here we obtained the genomic binding occupancy and expression data for Evi1 in human ovarian carcinoma cells. We identified numerous Evi1 target cancer genes and genes controlling cell migration and adhesion. Moreover, we characterized a transcriptional cooperation between AP1 and Evi1 that regulated proliferation and adhesion through a feed-forward loop. Furthermore, this study provides human genome-wide mapping and downstream analyses for Evi1 that will be useful for the research community. 16 samples were collected. Each condition was done in 4 replicates, collected 65 hours after transfection. Transfections with control siRNA or Flag-expressing vector were used as controls.

2012-01-15 | E-GEOD-25212 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data